In recent years, the rate of cardiovascular mortality following high-risk myocardial infarction has significantly declined.

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.